Longitudinal biomarkers in amyotrophic lateral sclerosis.

Fen HuangYuda ZhuJennifer Hsiao-NakamotoXinyan TangJason C DugasMiriam Moscovitch-LopatinJonathan D GlassRobert H BrownShafeeq S LadhaDavid LacomisJeffrey M HarrisKimberly Scearce-LevieCarole HoRobert BowserJames D Berry

Published in: Annals of clinical and translational neurology (2020)

Longitudinal stability of cytokines and NFs in PALS support their use for monitoring responses to immunomodulatory and neuroprotective treatments. NFs also have prognostic value for fast-progression patients and may be used to select similar patient subsets in clinical trials.

Keyphrases

clinical trial
end stage renal disease
ejection fraction
newly diagnosed
peritoneal dialysis
patient reported outcomes
open label
phase ii
blood brain barrier
double blind